Reason for request
Inclusion on the list of medicines refundable by National Health Insurance and approved for hospital use in the extension of indication: “treatment of unresectable or metastatic, well- or moderately-differentiated neuroendocrine tumours of pancreatic origin in adults with progressive disease”.
The actual benefit of AFINITOR is substantial.
Clinical Added Value
AFINITOR provides a minor IAB (level IV) in terms of efficacy in the therapeutic management of patients with advanced neuroendocrine tumours of pancreatic origin.
Évaluation des médicaments